Background: This community-based study was conducted to determine the proportion of individuals in the population that had been infected by the SARS-CoV-2 virus and developed antibodies before the second wave and introduction of COVID-19 vaccines in Nigeria. Methods:Between December 2020 and March 2021, 2,244 markets sellers and shoppers aged ≤ 70 years across six states [two northern (Kano and Kaduna), two eastern (Ebonyi and Imo), and two western (Oyo and Lagos)] regions were enrolled in the study. Demographic information was collected from the participants as well as whole blood which was separated into serum and tested for SARS-CoV-2 total antibodies with a validated ELISA kit (WANTAI SARS-CoV-2 Ab ELISA) approved by the U.S. Food and Drug Administration.Results: Overall, 1, 453 participants tested positive for the antibodies giving a seroprevalence of 66.8%. The antibodies were significantly (P = 0.0001) detected across the six states with the highest rate in Kano (83%) and the lowest rate in Lagos (39%). Participants who were ≤ 19 years and those between 60 and 69 years had the highest (68.42% (104/152) and lowest (56.20%: 68/121) seroprevalence rates respectively. In terms of religion, higher antibody levels were significantly (χ2 =17.4664, P = 0.0001) detected among Christians (75%: 576/766) compared to Muslims (65%: 395/609). There were no significant relationships between antibody positivity rates and gender, education, economic as well as marital status (p > 0.05). Conclusion:Six out of every ten participants in this study had antibodies against SARS-CoV-2 before the second wave and introduction of COVID-19 vaccines. Increased activities and mobility may be responsible for high levels of SARS-CoV-2 antibodies among young persons while differences in religious practices may account for the low prevalence of SARS-CoV-2 antibodies among Muslims compared to Christians.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.